Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRVS |
---|---|---|
09:32 ET | 627 | 2.12 |
09:50 ET | 300 | 2.18 |
09:57 ET | 100 | 2.145 |
10:19 ET | 5000 | 2.17 |
10:24 ET | 384 | 2.17 |
10:30 ET | 100 | 2.19 |
10:33 ET | 10611 | 2.175 |
10:37 ET | 800 | 2.16 |
11:09 ET | 171 | 2.1117 |
11:11 ET | 200 | 2.1425 |
11:13 ET | 300 | 2.1299 |
11:22 ET | 400 | 2.13 |
11:54 ET | 3400 | 2.125 |
12:00 ET | 400 | 2.125 |
12:09 ET | 200 | 2.1358 |
12:36 ET | 200 | 2.14 |
12:38 ET | 100 | 2.125 |
12:39 ET | 406 | 2.11 |
12:45 ET | 525 | 2.13 |
12:52 ET | 3132 | 2.12 |
12:56 ET | 260 | 2.1 |
01:10 ET | 100 | 2.09 |
01:19 ET | 300 | 2.09 |
01:30 ET | 100 | 2.13 |
01:44 ET | 285 | 2.112 |
02:13 ET | 500 | 2.135 |
02:15 ET | 2000 | 2.12 |
02:31 ET | 300 | 2.1467 |
02:49 ET | 237 | 2.12 |
02:51 ET | 151 | 2.14 |
03:02 ET | 200 | 2.15 |
03:07 ET | 3035 | 2.14 |
03:14 ET | 100 | 2.12 |
03:18 ET | 127 | 2.14 |
03:23 ET | 100 | 2.12 |
03:36 ET | 110 | 2.1404 |
03:39 ET | 100 | 2.15 |
03:48 ET | 500 | 2.1484 |
03:59 ET | 200 | 2.16 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Corvus Pharmaceuticals Inc | 135.1M | -4.2x | --- |
Tevogen Bio Holdings Inc | 134.1M | -1,877.9x | --- |
Gossamer Bio Inc | 133.5M | -0.6x | --- |
RAPT Therapeutics Inc | 139.5M | -1.3x | --- |
Citius Pharmaceuticals Inc | 126.0M | -2.9x | --- |
Cardiff Oncology Inc | 142.2M | -3.5x | --- |
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $135.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 62.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.10 |
EPS | $-0.51 |
Book Value | $0.79 |
P/E Ratio | -4.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.